Benzinga · Aug 27, 2026
Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $57
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $56 to $57.
PA
NASDAQ · PAVM
PAVmed Inc.
Healthcare · Medical - Devices
$4.18
Down-$0.09 (-2.11%)
Updated Sep 14, 2026, 7:12 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.07M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $3.85 – $10.80
- Volume
- 7.91K
- Avg. volume
- 505.07K
Price performance
PAVM price history
1M range · 19 trading sessions · Daily adjusted prices
PAVM closed at $4.18 after 19 trading sessions, down 21.50% for the selected period.
- Last close
- $4.18
- Period change
- -21.50%
- Period low
- $4.18
- Period high
- $5.35
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $4.22 | $4.305 | $4.14 | $4.18 | 7.91K |
| Sep 10, 2026 | $4.44 | $4.62 | $4.11 | $4.27 | 23.92K |
| Sep 9, 2026 | $4.9071 | $4.9071 | $4.375 | $4.52 | 11.43K |
| Sep 8, 2026 | $4.9671 | $5.40 | $4.70 | $4.72 | 98.95K |
| Sep 4, 2026 | $5.02 | $5.38 | $4.90 | $5.28 | 66.49K |
| Sep 3, 2026 | $5.25 | $5.36 | $5.05 | $5.09 | 5.75K |
| Sep 2, 2026 | $5.025 | $5.65 | $5.025 | $5.35 | 7K |
| Sep 1, 2026 | $5.13 | $5.13 | $4.925 | $4.99 | 4.21K |
| Aug 31, 2026 | $5.08 | $5.21 | $4.90 | $5.21 | 31.44K |
| Aug 28, 2026 | $5.09 | $5.15 | $4.92 | $4.92 | 10.36K |
| Aug 27, 2026 | $5.44 | $5.5999 | $5.07 | $5.07 | 11.18K |
| Aug 26, 2026 | $5.41 | $5.42 | $5.32 | $5.32 | 1.22K |
| Aug 25, 2026 | $5.15 | $5.31 | $5.05 | $5.275 | 5.66K |
| Aug 24, 2026 | $5.03 | $5.24 | $5.01 | $5.10 | 17.5K |
| Aug 21, 2026 | $5.09 | $5.40 | $5.09 | $5.175 | 6.11K |
| Aug 20, 2026 | $5.19 | $5.55 | $5.09 | $5.18 | 23.84K |
| Aug 19, 2026 | $5.04 | $5.29 | $4.9144 | $5.10 | 22.09K |
| Aug 18, 2026 | $5.0796 | $5.17 | $5.06 | $5.06 | 3.46K |
| Aug 17, 2026 | $5.2699 | $5.40 | $4.75 | $5.325 | 21.3K |
Latest PAVM news
The latest Smart Investors Daily articles mentioning PAVM.
Stock researchCompany · Overview
PAVM research
Overview
Company profile and research snapshot.
Company profile
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Ascendiant Capital | Buy | — |
| Jun 8, 2026 | Ascendiant Capital | Buy | — |
| Apr 9, 2026 | Ascendiant Capital | Buy | — |
| Dec 10, 2025 | Ascendiant Capital | Buy | — |
| Oct 6, 2025 | Ascendiant Capital | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 17, 2026
PAVmed Inc. 2026 Q2 - Results - Earnings Call Presentation
SeekingAlpha · Aug 14, 2026
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Q2 2026 Earnings Call August 14, 2026 8:30 AM EDTCompany ParticipantsMatthew Riley - Senior Director of Investor RelationsLishan Aklog -...
Benzinga · Aug 14, 2026
PAVmed Q2 2026 Earnings Call: Complete Transcript
On Friday, PAVmed (NASDAQ:PAVM) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
